Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A Report From the Children's Oncology Group - Concepedia

Concepedia

Publication | Open Access

Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A Report From the Children's Oncology Group

DOI Full Paper Access

137

Citations

23

References

2005

Year

Mark L. Bernstein, Meenakshi Devidas, Dominique Lafreniere, Abdul-Kader Souid, Paul A. Meyers, Mark C. Gebhardt, Kimo C. Stine, Richard W. Nicholas, Elizabeth J. Perlman, Ronald L. Dubowy,

Journal of Clinical Oncology

Abstract

Topotecan had limited activity in patients with Ewing sarcoma or PNET metastatic at diagnosis. The topotecan-cyclophosphamide combination was active. Amifostine was not myeloprotective. Overall results showed no improvement compared with previous studies.

References

	Year	Citations

Page 1